232 related articles for article (PubMed ID: 29337841)
1. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children.
Forbes-Amrhein MM; Dillman JR; Trout AT; Koch BL; Dickerson JM; Giordano RM; Towbin AJ
Invest Radiol; 2018 May; 53(5):313-318. PubMed ID: 29337841
[TBL] [Abstract][Full Text] [Related]
2. Adverse allergic reactions to linear ionic gadolinium-based contrast agents: experience with 194, 400 injections.
Aran S; Shaqdan KW; Abujudeh HH
Clin Radiol; 2015 May; 70(5):466-75. PubMed ID: 25626627
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of multiple administrations of gadopentetate dimeglumine or gadoterate meglumine on brain T1-weighted hyperintensity in pediatric patients.
Towbin AJ; Zhang B; Dillman JR
Pediatr Radiol; 2021 Dec; 51(13):2568-2580. PubMed ID: 34286351
[TBL] [Abstract][Full Text] [Related]
4. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
5. Breakthrough Reactions to Gadobenate Dimeglumine.
Bhatti ZS; Mervak BM; Dillman JR; Davenport MS
Invest Radiol; 2018 Sep; 53(9):551-554. PubMed ID: 29470193
[TBL] [Abstract][Full Text] [Related]
6. Reactions to Both Nonionic Iodinated and Gadolinium-Based Contrast Media: Incidence and Clinical Characteristics.
Sodagari F; Mozaffary A; Wood CG; Schmitz B; Miller FH; Yaghmai V
AJR Am J Roentgenol; 2018 Apr; 210(4):715-719. PubMed ID: 29412016
[TBL] [Abstract][Full Text] [Related]
7. Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions.
Davenport MS; Dillman JR; Cohan RH; Hussain HK; Khalatbari S; McHugh JB; Ellis JH
Radiology; 2013 Mar; 266(3):773-82. PubMed ID: 23238152
[TBL] [Abstract][Full Text] [Related]
8. Gadoxetate Disodium versus Gadoterate Meglumine: Quantitative Respiratory and Hemodynamic Metrics by Using Compressed-Sensing MRI.
Glessgen CG; Moor M; Stieltjes B; Winkel DJ; Block TK; Merkle EM; Heye TJ; Boll DT
Radiology; 2019 Nov; 293(2):317-326. PubMed ID: 31549944
[TBL] [Abstract][Full Text] [Related]
9. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
10. Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations.
De Ridder F; De Maeseneer M; Stadnik T; Luypaert R; Osteaux M
JBR-BTR; 2001 Aug; 84(4):150-2. PubMed ID: 11688727
[TBL] [Abstract][Full Text] [Related]
11. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
Abujudeh HH; Kosaraju VK; Kaewlai R
AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606
[TBL] [Abstract][Full Text] [Related]
12. Incidence and severity of acute adverse reactions to four different gadolinium-based MR contrast agents.
Okigawa T; Utsunomiya D; Tajiri S; Okumura S; Sasao A; Wada H; Oda S; Arimura H; Hayashida E; Urata J; Yamashita Y
Magn Reson Med Sci; 2014; 13(1):1-6. PubMed ID: 24492735
[TBL] [Abstract][Full Text] [Related]
13. Clinical safety of gadopentetate dimeglumine.
Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study.
Heinrich MC; Kuhlmann MK; Kohlbacher S; Scheer M; Grgic A; Heckmann MB; Uder M
Radiology; 2007 Feb; 242(2):425-34. PubMed ID: 17179401
[TBL] [Abstract][Full Text] [Related]
17. [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].
Campos A; Aznar L; Alamar R; Castelló JV
Med Clin (Barc); 1996 Feb; 106(5):197. PubMed ID: 8684023
[No Abstract] [Full Text] [Related]
18. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study.
Parillo M; Sapienza M; Arpaia F; Magnani F; Mallio CA; DʼAlessio P; Quattrocchi CC
Invest Radiol; 2019 Apr; 54(4):191-197. PubMed ID: 30379729
[TBL] [Abstract][Full Text] [Related]
19. Potential neurotoxic effects of gadopentetate dimeglumine: clinical significance.
Alhassan A; Weinmann HJ
AJNR Am J Neuroradiol; 1997 Apr; 18(4):785-6; author reply 786-8. PubMed ID: 9127052
[No Abstract] [Full Text] [Related]
20. Intraindividual Analysis of Signal Intensity Changes in the Dentate Nucleus After Consecutive Serial Applications of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Radbruch A; Weberling LD; Kieslich PJ; Hepp J; Kickingereder P; Wick W; Schlemmer HP; Bendszus M
Invest Radiol; 2016 Nov; 51(11):683-690. PubMed ID: 27495187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
